BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bristol-Myers Squibb Company (BMY)'s Sprycel Wins European Market Approval for Chronic Myeloid Leukemia


12/10/2010 7:51:51 AM

Wall Street Journal -- Bristol-Myers Squibb Co.'s (BMY) cancer drug Sprycel has been given marketing approval in Europe for the treatment of so-called Philadelphia chromosome positive chronic phase chronic myeloid leukemia, or CML. Sprycel, also known by its active ingredient name dasatinib, is the first new treatment to be approved in the European Union with superior efficacy to Novartis AG's (NOVN.VX, NVS) Gleevec in this indication since 2001, the U.S. drug maker said in a statement.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->